Gilead Sciences CEO O'Day sells 30,881 shares

Q: How many GILD shares did Daniel Patrick O'Day sell?

Daniel Patrick O'Day reported six sales totaling 30,881 Gilead common shares on October 30 and November 2, 2026. The reported transactions were made under a Rule 10b5-1 plan adopted February 25, 2026.

Q: How many GILD options remained after Daniel Patrick O'Day's exercise?

The option record reports 240,739 options following his October 30, 2026 exercise of options for 15,881 common shares.

Daniel Patrick O'Day, Gilead Sciences, Inc.'s Chairman & CEO and a director, reported six sales totaling 30,881 shares on October 30 and November 2, 2026, under a Rule 10b5-1 trading plan adopted February 25, 2026.

Available on EDGAR 11/02/2026 - 07:15 PM EST Accepted by SEC EDGAR 11/02/2026 - 07:14 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Very Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Daniel Patrick O'Day, Gilead Sciences, Inc.'s Chairman & CEO and a director, reported six sales totaling 30,881 shares on October 30 and November 2, 2026, under a Rule 10b5-1 trading plan adopted February 25, 2026.

On October 30, he exercised non-qualified options for 15,881 shares at a $72.34 exercise price and sold those shares at the reported price of $175.2456 per share. The option record reports 240,739 options following the exercise.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 8 txns

Insider O'Day Daniel Patrick

Role Chairman & CEO

Sold 30,881 shs ($5.33M)

Approx. gross sale proceeds $5.33M

Approx. exercise cost $1.15M

Share of Position Sold 5.3%

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F3}	1,600	$167.3999	$268K
Sale	Common Stock ^{F1, F4}	1,700	$168.1006	$286K
Sale	Common Stock ^{F1, F5}	1,904	$169.2733	$322K
Sale	Common Stock ^{F1, F6}	7,796	$170.3527	$1.33M
Sale	Common Stock ^{F1, F7}	2,000	$171.0627	$342K
Exercise	Non-qualified Stock Option (Right to Buy) ^{F1, F8}	15,881	$0.00	$0.00
Exercise	Common Stock ^F1	15,881	$72.34	$1.15M
Sale	Common Stock ^{F1, F2}	15,881	$175.2456	$2.78M

Holdings After Transaction: Non-qualified Stock Option (Right to Buy) — 240,739 contracts (Direct); Common Stock — 551,683 shares (Direct)

Holdings Before and After: Non-qualified Stock Option (Right to Buy), 256,620 to 240,739 contracts (Direct); Common Stock, 566,683 to 551,683 shares (Direct)

Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (8)

F1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
F2. Sale prices for the transactions reported range from $175.05 to $175.45. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F3. Sale prices for the transactions reported range from $166.69 to $167.66. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F4. Sale prices for the transactions reported range from $167.72 to $168.68. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F5. Sale prices for the transactions reported range from $168.78 to $169.77. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F6. Sale prices for the transactions reported range from $169.83 to $170.82. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F7. Sale prices for the transactions reported range from $170.83 to $171.27. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F8. The stock options have a four-year vesting schedule. 25% of the stock options vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Key Figures

Shares sold: 30,881 shares Shares acquired through option exercise: 15,881 shares Exercise price: $72.34 per share +2 more

5 metrics

Shares sold 30,881 shares Across six sales on October 30 and November 2, 2026

Shares acquired through option exercise 15,881 shares October 30, 2026

Exercise price $72.34 per share Options exercised October 30, 2026

Reported sale price $175.2456 per share Sale of 15,881 shares on October 30, 2026

Options following exercise 240,739 options Reported after the October 30, 2026 exercise

Key Terms

Rule 10b5-1 trading plan, Non-qualified Stock Option (Right to Buy), four-year vesting schedule

3 terms

Rule 10b5-1 trading plan financial

"made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Non-qualified Stock Option (Right to Buy) financial

"Non-qualified Stock Option (Right to Buy)"

four-year vesting schedule financial

"The stock options have a four-year vesting schedule."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GILD shares did Daniel Patrick O'Day sell?

Daniel Patrick O'Day reported six sales totaling 30,881 Gilead common shares on October 30 and November 2, 2026. The reported transactions were made under a Rule 10b5-1 plan adopted February 25, 2026.

How many GILD options remained after Daniel Patrick O'Day's exercise?

The option record reports 240,739 options following his October 30, 2026 exercise of options for 15,881 common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Day Daniel Patrick

(Last)

(First)

(Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY

CALIFORNIA

94404

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairman & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/30/2026		M⁽¹⁾		15,881	A	$72.34	582,564	D
Common Stock	10/30/2026		S⁽¹⁾		15,881	D	$175.2456⁽²⁾	566,683	D
Common Stock	11/02/2026		S⁽¹⁾		1,600	D	$167.3999⁽³⁾	565,083	D
Common Stock	11/02/2026		S⁽¹⁾		1,700	D	$168.1006⁽⁴⁾	563,383	D
Common Stock	11/02/2026		S⁽¹⁾		1,904	D	$169.2733⁽⁵⁾	561,479	D
Common Stock	11/02/2026		S⁽¹⁾		7,796	D	$170.3527⁽⁶⁾	553,683	D
Common Stock	11/02/2026		S⁽¹⁾		2,000	D	$171.0627⁽⁷⁾	551,683	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-qualified Stock Option (Right to Buy)	$72.34	10/30/2026		M⁽¹⁾			15,881	⁽⁸⁾	03/10/2030	Common Stock	15,881	$0	240,739	D

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

2. Sale prices for the transactions reported range from $175.05 to $175.45. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

3. Sale prices for the transactions reported range from $166.69 to $167.66. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

4. Sale prices for the transactions reported range from $167.72 to $168.68. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

5. Sale prices for the transactions reported range from $168.78 to $169.77. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

6. Sale prices for the transactions reported range from $169.83 to $170.82. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

7. Sale prices for the transactions reported range from $170.83 to $171.27. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

8. The stock options have a four-year vesting schedule. 25% of the stock options vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Remarks:

	/s/ Amy Kim by Power of Attorney for Daniel O'Day	11/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR